SCHEMBL3635536

SCHEMBL3635536

O=C1NC(=O)C(c2cccc(-c3ccc(C(=O)O)cc3)c2)N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 1/20 0.45
RARB P10826 1/20 0.45
RARG P13631 1/20 0.45
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
RXRA P19793 4/20 0.43
RXRB P28702 4/20 0.43
RXRG P48443 1/20 0.43
BCL2 P10415 1/20 0.43
TDP2 O95551 2/20 0.43
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41
GRIK3 Q13003 1/20 0.41
EGFR P00533 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
KMO O15229 1/20 0.41
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475331 0.85 KMT2A (0.46) TDP2TDP1GAAKDM4EALDH1A1
SCHEMBL7544189 0.81 TDP1 (0.61) TDP1GAAKDM4EALDH1A1MAPT
SCHEMBL1624200 0.76 TDP1 (0.62) TDP1GAAKDM4EALDH1A1POLB
SCHEMBL8076297 0.73 KIF11 (0.56) TDP1GAAALDH1A1POLBMAPT
SCHEMBL873282 0.72 HTT (0.51) KMOGAAKDM4EALDH1A1POLB
SCHEMBL19955179 0.72 TDP1 (0.66) TDP1GAAKDM4EALDH1A1POLB
SCHEMBL31738422 0.72 TDP1 (0.66) TDP1GAAKDM4EALDH1A1POLB
SCHEMBL395878 0.72 TDP1 (0.66) TDP1GAAKDM4EALDH1A1POLB
SCHEMBL30066684 0.72 KMO (0.72) RARARARBRARGTRIM24TRIM33
SCHEMBL16166011 0.72 KMO (0.72) RARARARBRARGTRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 EP claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO claimed
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 EP disclosed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 US disclosed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 RARA 1436/4885RARB 1891/4885RARG 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.